 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Akero Therapeutics, Inc. (AKRO) is a cardio-metabolic nonalcoholic steatohepatitis (NASH) company. 
The company engages in the development of medicines designed to restore metabolic balance and improve overall health.
The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body.
It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. Shares have formed a bullish "flag" following sale of shares. The company announced closing of its previously announced upsized underwritten public offering of 8,846,154 shares of its common stock at a public offering price of $26.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 1,153,846 shares of common stock in this offering. Higher share prices are expected.
Entry Point: $26.00
Stop Loss: $24.70
Trading Range: $7.52 - $29.78
Target Price: $29.00
